FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1445-1447 September 30, 2004 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Walsh, T. J. PubMed Citation

Empirical antibacterial therapy for fever and neutropenia has dramatically improved outcomes in a large number of patients, making it possible for many to undergo successful antineoplastic therapy. Because the diagnosis of fungal infection in patients with neutropenia can be difficult and because delays in instituting effective antifungal therapy are associated with increased mortality, the concept of empirical antifungal therapy with amphotericin B has emerged. Empirical antifungal therapy has become accepted clinical practice, and there are now alternatives to conventional amphotericin B — namely, liposomal amphotericin B and voriconazole.¹

In this issue of the Journal, Walsh et al.² report the results . . . [Full Text of this Article]

Source Information

From the Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels.

Related Letters:

Caspofungin versus Liposomal Amphotericin B for Empirical Therapy
Kontoyiannis D. P., Lewis R. E., Tattevin P., Bareau B., Camus C., Marty F. M., Lowry C. M., Schneemann M., Imhof A., Danaher P. J., Jones B. L., McLintock L. A., Walsh T. J., Donowitz G. R., dePauw B. E.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:410-414, Jan 27, 2005. Correspondence

This article has been cited by other articles:

• Chowdhry, R., Marshall, W. L. (2008). Analytical Reviews: Antifungal Therapies in the Intensive Care Unit. J Intensive Care Med 23: 151-158 [Abstract]  
• Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 2.. Am J Health Syst Pharm 63: 1813-1820 [Abstract] [Full Text]  
• Chen, C.-Y., Kumar, R. N., Feng, Y.-H., Ho, C.-H., You, J.-Y., Liao, C.-C., Tseng, C.-H., Mavros, P., Gerth, W. C., Chen, Y.-C. (2006). Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J Antimicrob Chemother 57: 1181-1188 [Abstract] [Full Text]  
• Kontoyiannis, D. P., Lewis, R. E., Tattevin, P., Bareau, B., Camus, C., Marty, F. M., Lowry, C. M., Schneemann, M., Imhof, A., Danaher, P. J., Jones, B. L., McLintock, L. A., Walsh, T. J., Donowitz, G. R., dePauw, B. E. (2005). Caspofungin versus liposomal amphotericin B for empirical therapy.. NEJM 352: 410-414 [Full Text]  
• (2004). Caspofungin Efficacious for Empirical Use in Febrile Neutropenia. JWatch Infect. Diseases 2004: 1-1 [Full Text]